Amundi trimmed its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 68.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,663 shares of the company's stock after selling 181,803 shares during the quarter. Amundi owned 0.05% of Alkermes worth $2,378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. Loomis Sayles & Co. L P grew its position in Alkermes by 365.5% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company's stock worth $52,704,000 after purchasing an additional 1,478,422 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in shares of Alkermes in the third quarter valued at approximately $16,126,000. Raymond James Financial Inc. purchased a new stake in shares of Alkermes during the fourth quarter valued at approximately $12,293,000. C WorldWide Group Holding A S bought a new stake in Alkermes during the fourth quarter worth $7,190,000. Finally, Barclays PLC boosted its position in Alkermes by 108.8% in the third quarter. Barclays PLC now owns 423,931 shares of the company's stock worth $11,867,000 after purchasing an additional 220,893 shares during the last quarter. Institutional investors own 95.21% of the company's stock.
Alkermes Price Performance
ALKS stock traded down $0.39 during midday trading on Thursday, reaching $33.96. The company had a trading volume of 910,178 shares, compared to its average volume of 1,689,179. The firm has a 50-day moving average price of $32.73 and a 200-day moving average price of $29.97. The company has a market capitalization of $5.52 billion, a P/E ratio of 15.65, a P/E/G ratio of 2.20 and a beta of 0.62. Alkermes plc has a 1 year low of $22.90 and a 1 year high of $36.45.
Alkermes (NASDAQ:ALKS - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. On average, equities analysts predict that Alkermes plc will post 1.31 EPS for the current year.
Insider Buying and Selling
In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the sale, the executive vice president now directly owns 57,875 shares in the company, valued at $2,056,298.75. This represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.89% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
ALKS has been the topic of a number of research analyst reports. StockNews.com raised shares of Alkermes from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 13th. Royal Bank of Canada initiated coverage on shares of Alkermes in a report on Thursday, March 13th. They issued a "sector perform" rating and a $40.00 price target on the stock. The Goldman Sachs Group increased their price objective on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 14th. Deutsche Bank Aktiengesellschaft started coverage on shares of Alkermes in a report on Tuesday, February 11th. They set a "buy" rating and a $40.00 price objective on the stock. Finally, HC Wainwright reiterated a "neutral" rating and issued a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Alkermes currently has an average rating of "Moderate Buy" and an average price target of $38.46.
Check Out Our Latest Research Report on Alkermes
Alkermes Profile
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Stories
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
